The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antidiabetic SGLT-2 Inhibitor Market Research Report 2025
Synopsis
The global Antidiabetic SGLT-2 Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Antidiabetic SGLT-2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic SGLT-2 Inhibitor.
Report Scope
The Antidiabetic SGLT-2 Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic SGLT-2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidiabetic SGLT-2 Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Canagliflozin
Empagliflozin
Dapagliflozin
Other
Segment by Application
Hospitals
Clinics
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic SGLT-2 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Antidiabetic SGLT-2 Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
This report aims to provide a comprehensive presentation of the global market for Antidiabetic SGLT-2 Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antidiabetic SGLT-2 Inhibitor.
Report Scope
The Antidiabetic SGLT-2 Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antidiabetic SGLT-2 Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antidiabetic SGLT-2 Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Segment by Type
Canagliflozin
Empagliflozin
Dapagliflozin
Other
Segment by Application
Hospitals
Clinics
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antidiabetic SGLT-2 Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antidiabetic SGLT-2 Inhibitor Market Overview
1.1 Product Overview and Scope of Antidiabetic SGLT-2 Inhibitor
1.2 Antidiabetic SGLT-2 Inhibitor Segment by Type
1.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Value Comparison by Type (2024-2030)
1.2.2 Canagliflozin
1.2.3 Empagliflozin
1.2.4 Dapagliflozin
1.2.5 Other
1.3 Antidiabetic SGLT-2 Inhibitor Segment by Application
1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Antidiabetic SGLT-2 Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Antidiabetic SGLT-2 Inhibitor Revenue 2019-2030
1.4.2 Global Antidiabetic SGLT-2 Inhibitor Sales 2019-2030
1.4.3 Global Antidiabetic SGLT-2 Inhibitor Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antidiabetic SGLT-2 Inhibitor Market Competition by Manufacturers
2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antidiabetic SGLT-2 Inhibitor Average Price by Manufacturers (2019-2024)
2.4 Global Antidiabetic SGLT-2 Inhibitor Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antidiabetic SGLT-2 Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antidiabetic SGLT-2 Inhibitor, Product Type & Application
2.7 Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
2.7.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antidiabetic SGLT-2 Inhibitor Players Market Share by Revenue
2.7.3 Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario by Region
3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antidiabetic SGLT-2 Inhibitor Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2019-2030
3.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2019-2024
3.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Region: 2025-2030
3.3 Global Antidiabetic SGLT-2 Inhibitor Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2019-2030
3.3.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2019-2024
3.3.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Region: 2025-2030
3.4 North America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.4.1 North America Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2030)
3.4.3 North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.5.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2030)
3.5.3 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.6.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2030)
3.6.3 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2030)
3.7.3 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2030)
4.1.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2019-2024)
4.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2025-2030)
4.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2019-2030)
4.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2030)
4.2.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2019-2024)
4.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2025-2030)
4.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2019-2030)
4.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2030)
5.1.1 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2019-2024)
5.1.2 Global Antidiabetic SGLT-2 Inhibitor Sales by Application (2025-2030)
5.1.3 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2019-2030)
5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2030)
5.2.1 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2019-2024)
5.2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2025-2030)
5.2.3 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2019-2030)
5.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Johnson & Johnson
6.3.1 Johnson & Johnson Corporation Information
6.3.2 Johnson & Johnson Description and Business Overview
6.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.3.5 Johnson & Johnson Recent Developments/Updates
6.4 GlaxoSmithKline
6.4.1 GlaxoSmithKline Corporation Information
6.4.2 GlaxoSmithKline Description and Business Overview
6.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.4.5 GlaxoSmithKline Recent Developments/Updates
6.5 Merck & Co
6.5.1 Merck & Co Corporation Information
6.5.2 Merck & Co Description and Business Overview
6.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.5.5 Merck & Co Recent Developments/Updates
6.6 Eli Lilly
6.6.1 Eli Lilly Corporation Information
6.6.2 Eli Lilly Description and Business Overview
6.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.6.5 Eli Lilly Recent Developments/Updates
6.7 Sanofi
6.6.1 Sanofi Corporation Information
6.6.2 Sanofi Description and Business Overview
6.6.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.7.5 Sanofi Recent Developments/Updates
6.8 Takeda Pharmaceuticals
6.8.1 Takeda Pharmaceuticals Corporation Information
6.8.2 Takeda Pharmaceuticals Description and Business Overview
6.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.8.5 Takeda Pharmaceuticals Recent Developments/Updates
6.9 Novo Nordisk
6.9.1 Novo Nordisk Corporation Information
6.9.2 Novo Nordisk Description and Business Overview
6.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.9.5 Novo Nordisk Recent Developments/Updates
6.10 Servier Laboratories
6.10.1 Servier Laboratories Corporation Information
6.10.2 Servier Laboratories Description and Business Overview
6.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.10.5 Servier Laboratories Recent Developments/Updates
6.11 Boehringer Ingelheim
6.11.1 Boehringer Ingelheim Corporation Information
6.11.2 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Description and Business Overview
6.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.11.5 Boehringer Ingelheim Recent Developments/Updates
6.12 Bristol-Myers Squibb
6.12.1 Bristol-Myers Squibb Corporation Information
6.12.2 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Description and Business Overview
6.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio
6.12.5 Bristol-Myers Squibb Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antidiabetic SGLT-2 Inhibitor Industry Chain Analysis
7.2 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antidiabetic SGLT-2 Inhibitor Production Mode & Process
7.4 Antidiabetic SGLT-2 Inhibitor Sales and Marketing
7.4.1 Antidiabetic SGLT-2 Inhibitor Sales Channels
7.4.2 Antidiabetic SGLT-2 Inhibitor Distributors
7.5 Antidiabetic SGLT-2 Inhibitor Customers
8 Antidiabetic SGLT-2 Inhibitor Market Dynamics
8.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
8.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
8.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
8.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
